Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

PURPOSE: Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma. We assessed whether biologic subtype according to primary tumor type or genomic subtype can funct...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Rose, April A N, Armstrong, Susan M, Hogg, David, Butler, Marcus O, Saibil, Samuel D, Arteaga, Diana P, Pimentel Muniz, Thiago, Kelly, Deirdre, Ghazarian, Danny, King, Ian, Kamil, Zaid Saeed, Ross, Kendra, Spreafico, Anna
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Immunotherapy Biomarkers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7831745/
https://ncbi.nlm.nih.gov/pubmed/33483342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001642
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars